Enhabit, Inc. (NYSE:EHAB) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced its position in shares of Enhabit, Inc. (NYSE:EHAB) by 74.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 78,574 shares of the company’s stock after selling 226,671 shares during the period. JPMorgan Chase & Co. owned approximately 0.16% of Enhabit worth $614,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of EHAB. Rhumbline Advisers increased its position in Enhabit by 2.8% during the fourth quarter. Rhumbline Advisers now owns 80,760 shares of the company’s stock worth $631,000 after buying an additional 2,211 shares in the last quarter. Stoneridge Investment Partners LLC lifted its stake in shares of Enhabit by 22.6% in the 4th quarter. Stoneridge Investment Partners LLC now owns 12,533 shares of the company’s stock valued at $98,000 after purchasing an additional 2,308 shares in the last quarter. Intech Investment Management LLC increased its position in shares of Enhabit by 27.6% in the fourth quarter. Intech Investment Management LLC now owns 15,481 shares of the company’s stock worth $121,000 after acquiring an additional 3,353 shares in the last quarter. Franklin Resources Inc. raised its position in Enhabit by 19.6% in the third quarter. Franklin Resources Inc. now owns 32,382 shares of the company’s stock valued at $256,000 after purchasing an additional 5,317 shares during the period. Finally, Quantbot Technologies LP acquired a new position in Enhabit during the 4th quarter worth approximately $45,000.

Enhabit Stock Up 0.2 %

EHAB opened at $7.95 on Wednesday. Enhabit, Inc. has a 12 month low of $6.85 and a 12 month high of $10.70. The stock has a market cap of $401.06 million, a P/E ratio of -3.42 and a beta of 1.60. The stock’s 50 day moving average price is $8.29 and its 200 day moving average price is $8.01. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.46 and a quick ratio of 1.46.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reaffirmed a “buy” rating on shares of Enhabit in a research report on Thursday, March 6th.

Enhabit Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.